Set for removing wrinkles and / or enhancing skin elasticity and its application

Abstract

The present invention provides a set for removing wrinkles and / or enhancing skin elasticity, which comprises: (i) dosage form A, the dosage form A comprising: 10-20% by weight of an oil, 3-25% by weight of hydrogenated polydimethylsiloxane, 5-35% by weight of vinyl polydimethylsiloxane, 1-10% by weight of an emulsifier, 1-10% by weight of silica, and a carrier acceptable in the cosmetic field; and (ii) dosage form B, the dosage form B comprising: 1-10% by weight of a colloidal platinum composition, 1-10% by weight of light-scattering particles, a carrier acceptable in the cosmetic field; wherein the colloidal platinum composition comprises: 0.1-10% by weight of a metal platinum salt, 1-20% by weight of a fatty acid having 8-30 carbon atoms, 0.01-5% by weight of an organosilane having 10-60 carbon atoms, a solvent acceptable in the cosmetic field, and the solvent is propylene glycol. The present invention also relates to the application of the set in the cosmetic field.

Description

Technical Field

[0001] The present invention relates to the field of cosmetics, and in particular to a set for removing wrinkles and / or improving skin elasticity and applications thereof. Background Art

[0002] Aging is an inevitable, natural process of life, influenced by a variety of factors, including genetics, the environment, and social psychology. Wrinkles are the outward manifestation of aging on the skin, linked to factors such as skin laxity, UV exposure, gravity, repeated contraction of facial muscles, and inherent muscle tension. Wrinkles not only signal the indelible signs of aging but also severely impact the skin's aesthetics and even a person's social and psychological well-being. They can easily trigger negative emotions such as anxiety, depression, low self-esteem, and panic, thus impacting quality of life. They are a major threat to those who value beauty.

[0003] Facial wrinkles primarily include forehead wrinkles, frown lines, crow's feet, and nasolabial wrinkles. Crow's feet, which appear between the corners of the eyes and temples, are so similar in pattern to the lines on a fish's tail that they are nicknamed "crow's feet." Crow's feet are a sign of physiological aging, typically occurring in people over 30 and more pronounced in middle-aged and elderly women. Wrinkle formation is the most common manifestation of facial aging.

[0004] Skin elasticity is a key indicator of skin health. Elasticity in various parts of the skin decreases with age. Age increases, and the skin elasticity parameter decreases, leading to decreased elasticity. This is most noticeable around the corners of the eyes. Improving skin elasticity to delay aging is a continuing research and development focus in cosmetics.

[0005] Patent CN108904414 describes a fast-removing wrinkle eye cream that achieves the effect of firming the skin and instantly reducing wrinkles by adding three active ingredients: acetyl hexapeptide-8, SYN-COLL, and SYN-AKE; Patent CN108670896 describes an instant anti-wrinkle polypeptide eye cream that, by adding VP / VA copolymer and fine algae polysaccharides, can form a breathable film around the skin of the eyes and fill the wrinkle area of the eyes to achieve its effect; Patent CN109820782 describes an essence with good instant wrinkle-removing effect. It uses a microemulsion formulation as a thermodynamically stable system to make the active ingredients more easily absorbed and utilized by the skin to achieve its efficacy.

[0006] There are a wide variety of eye products on the market, but they often take dozens of days or even months to show any effectiveness. Furthermore, the results aren't always satisfactory. Currently, there are few products on the market that can improve crow's feet and reduce skin elasticity within 15 minutes of application.

[0007] Therefore, there is a need in the art to develop a new product for wrinkle removal and / or skin elasticity enhancement, which can remove wrinkles and enhance skin elasticity in a short time. Summary of the Invention

[0008] On the one hand, the present invention provides a set for wrinkle removal and / or skin elasticity enhancement, which comprises:

[0009] (i) Dosage form A, wherein the dosage form A comprises:

[0010] 10 - 20% by weight of an oil,

[0011] 3 - 25% by weight of hydrogenated polydimethylsiloxane having a viscosity of 10 to 130 cSt at 25°C,

[0012] 5 - 35% by weight of vinyl polydimethylsiloxane having a viscosity of 55000 to 95000 cSt at 25°C,

[0013] 1 - 10% by weight of an emulsifier,

[0014] 1 - 10% by weight of silica, and

[0015] a carrier acceptable in the cosmetic field; and

[0016] (ii) Dosage form B, wherein the dosage form B comprises:

[0017] 1 - 10% by weight of a colloidal platinum composition,

[0018] 1 - 10% by weight of light-scattering particles,

[0019] a carrier acceptable in the cosmetic field;

[0020] wherein the colloidal platinum composition comprises:

[0021] 0.1 - 10% by weight of a metal platinum salt,

[0022] 1 - 20% by weight of a fatty acid having 8 - 30 carbon atoms,

[0023] 0.01 - 5% by weight of an organosilane having 10 - 60 carbon atoms,

[0024] a solvent acceptable in the cosmetic field, and the solvent is propylene glycol.

[0025] In a preferred embodiment, the emulsifier in the dosage form A is a polydimethylsiloxane PEG-10 / 15 crosslinked polymer.

[0026] In a preferred embodiment, the silica in Formulation A is selected from: silica, silylated silica, dimethylsilylated silica, polydimethylsiloxane silylated silica, hydrated silica or a combination thereof.

[0027] In a preferred embodiment, the colloidal platinum composition in Formulation B further comprises polyvinylpyrrolidone having a K value of 28 - 34.

[0028] In a preferred embodiment, the metal platinum salt in the colloidal platinum composition in Formulation B is selected from: chloroplatinic acid, potassium hexachloroplatinate, sodium chloroplatinate, platinum acetylacetonate or a combination thereof.

[0029] In a preferred embodiment, the fatty acid in the colloidal platinum composition in Formulation B is selected from: palmitic acid, oleic acid, stearic acid, lauric acid, behenic acid or a combination thereof.

[0030] In a preferred embodiment, the organosilane in the colloidal platinum composition in Formulation B is selected from: trimethoxyoctylsilane, triethoxyoctylsilane or a combination thereof.

[0031] In a preferred embodiment, the light-scattering particles in Formulation B are nylon-12 and isopropyl triisostearoyl titanate.

[0032] In a preferred embodiment, Formulation B further comprises the following components: silicone oil, silicone elastomer, emulsifier, polyol or a combination thereof.

[0033] In a preferred embodiment, the kit is in the form of a two-formulation package or two separate packages.

[0034] On the other hand, the present invention provides a method of using the kit, comprising evenly applying Formulation A onto the skin surface until absorbed, and then applying Formulation B onto the skin surface. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 A Primos photograph showing the eye wrinkles of a subject without applying the product of Application Example 1.

[0036] Figure 2 A Primos photograph showing the eye wrinkles of a subject 15 minutes after applying the product of Application Example 1. DETAILED DESCRIPTION

[0037] The present invention provides a set for removing wrinkles and / or enhancing skin elasticity that takes effect in a short time, comprising Formulation A and Formulation B. Formulation A is the product to be applied in the first step, which contains vinyl dimethicone, hydrogenated polydimethylsiloxane, and silica. Formulation B is the product to be applied in the second step, which contains colloidal platinum and light-scattering particles. After using the set for removing wrinkles and / or enhancing skin elasticity according to the present invention, immediate effects can be produced, for example, crow's feet in the eye area and skin elasticity can be significantly improved after 15 minutes.

[0038] After the tester uses the set for removing wrinkles and / or enhancing skin elasticity according to the present invention (for example, after 15 minutes), both the skin roughness and the average depth value of skin wrinkles are significantly improved. Therefore, the set of the present invention has the immediate efficacy of helping to improve skin roughness and skin wrinkles. At the same time, the skin elasticity of the tester is also significantly improved, so the product of the present invention also has the immediate efficacy of enhancing skin elasticity.

[0039] For the purpose of providing a more concise description, some numerical expressions given herein are not modified by the term "about". It should be understood that whether or not the term "about" is explicitly used, each quantity given herein is intended to refer to the actual given value, and is also intended to refer to the approximate value of these given values reasonably inferred by those of ordinary skill in the art, including the approximate values of these given values caused by experimental and / or measurement conditions.

[0040] For the purpose of providing a more concise description, some numerical expressions herein are described as a range from about X amount to about Y amount. It should be understood that when a range is recited, the range is not limited to the recited upper and lower limits, but should include the entire range from about X amount to about Y amount or any amount therebetween.

[0041] I. Dosage Form A

[0042] Formulation A in the set for removing wrinkles and / or enhancing skin elasticity that takes effect in a short time according to the present application is the product to be applied in the first step, and this product contains vinyl dimethicone, hydrogenated polydimethylsiloxane, an emulsifier, and optionally silica.

[0043] Siloxane

[0044] Formulation A of the set of the present invention contains vinyl dimethicone, whose INCI name is VINYLDIMETHICONE. The viscosity index requirement of the vinyl dimethicone used in the present invention is that the viscosity at 25 °C is 55,000 to 95,000 cSt. In a preferred embodiment, the viscosity of the vinyl dimethicone used in the present invention is 55,000 to 80,000 cSt. In a preferred embodiment, the viscosity of the vinyl dimethicone used in the present invention is 60,000 to 80,000 cSt.

[0045] In some embodiments of the present invention, the content of vinyl polydimethylsiloxane in Formulation A of the kit described in the present application is 5-50% by weight. In some embodiments of the present invention, Formulation A of the kit contains 5-35% by weight of vinyl polydimethylsiloxane. In some embodiments of the present invention, Formulation A of the kit contains 5-20% by weight of vinyl polydimethylsiloxane.

[0046] Formulation A of the kit of the present invention contains hydrogenated polydimethylsiloxane, the INCI name of which is HYDROGENDIMETHICONE. The viscosity index requirement of the hydrogenated polydimethylsiloxane used in the present invention is that the viscosity at 25 °C is 10 to 130 cSt. In a preferred embodiment, the viscosity of the hydrogenated polydimethylsiloxane used in the present invention is 15 to 100 cSt.

[0047] In some embodiments of the present invention, the content of hydrogenated polydimethylsiloxane in Formulation A of the kit described in the present application is 1-35% by weight. In some embodiments of the present invention, Formulation A of the kit contains 3-25% by weight of hydrogenated polydimethylsiloxane. In some embodiments of the present invention, Formulation A of the kit contains 5-20% by weight of hydrogenated polydimethylsiloxane.

[0048] Siloxanes (e.g., hydrogenated polydimethylsiloxane and / or vinyl polydimethylsiloxane in Formulation A) can crosslink in situ on the skin (e.g., by the action of colloidal platinum in Formulation B) to form a transparent invisible film, which has the properties of wrinkle removal, refinement, waterproofness, sweat resistance, etc.

[0049] Emulsifier

[0050] Formulation A of the kit of the present invention contains an emulsifier. In a specific embodiment, the emulsifier used in Formulation A is polydimethylsiloxane PEG-10 / 15 crosslinked polymer.

[0051] In some embodiments of the present invention, the content of polydimethylsiloxane PEG-10 / 15 crosslinked polymer in Formulation A of the kit described in the present application is 1-10% by weight. In some embodiments of the present invention, Formulation A of the kit contains 1-5% by weight of polydimethylsiloxane PEG-10 / 15 crosslinked polymer. In some embodiments of the present invention, Formulation A of the kit contains 2-5% by weight of polydimethylsiloxane PEG-10 / 15 crosslinked polymer.

[0052] Silica

[0053] The dosage form A of the kit of the present invention contains silica. The silica used in dosage form A is a general term, including silica, silylated silica, dimethylsilylated silica, polydimethylsiloxane silylated silica, hydrated silica, and other combinations.

[0054] In some embodiments of the present invention, the content of silica in dosage form A of the kit described in this application is 1-10% by weight. In some embodiments of the present invention, dosage form A of the kit contains 5-10% by weight of silica.

[0055] Other Ingredients in Dosage Form A

[0056] The dosage form A of the kit of the present invention may also contain other components. For example, dosage form A of the kit of this application may contain oils and fats, thickeners, preservatives, pH regulators, etc.

[0057] In some specific embodiments, the oil and fat contained in dosage form A of the kit is polydimethylsiloxane. In some preferred embodiments, the dosage of the oil and fat in dosage form A is 10-20% by weight.

[0058] In some specific embodiments, dosage form A of the kit contains acrylic acid (ester) / C10-30 alkyl acrylate cross-linked polymer. In some preferred embodiments, the dosage of acrylic acid (ester) / C10-30 alkyl acrylate cross-linked polymer in dosage form A is 0.1-5% by weight. In some preferred embodiments, the dosage of acrylic acid (ester) / C10-30 alkyl acrylate cross-linked polymer in dosage form A is 0.5-1.5% by weight.

[0059] In some specific embodiments, dosage form A of the kit contains phenoxyethanol. In some preferred embodiments, the dosage of phenoxyethanol in dosage form A is 0.1-1% by weight.

[0060] In some specific embodiments, dosage form A of the kit contains tromethamine. In some preferred embodiments, the dosage of tromethamine in dosage form A is 0.1-1% by weight.

[0061] Preparation Method of Dosage Form A

[0062] A method for preparing dosage form A is also provided in the present invention.

[0063] Dosage form A of the present invention can be prepared from the following raw materials in weight percentages: oil and fat 10-20%, hydrogenated polydimethylsiloxane 3-25%, vinyl polydimethylsiloxane 5-35%, silica 1-10%, emulsifier 2-5%, thickener 0.5-1.5%, preservative 0.1-1%, and deionized water 40-60%.

[0064] Specifically, the preparation method of dosage form A of the present invention comprises the following steps:

[0065] (a) Mix vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, silica, oil and emulsifier uniformly to form an oil phase;

[0066] (b) Take a part of deionized water, add a thickening agent, dissolve and swell it fully, and add other components such as a preservative to form an aqueous phase;

[0067] (c) Slowly add the aqueous phase to the oil phase to obtain dosage form A.

[0068] In a specific embodiment, the preparation process of dosage form A includes the following steps: within the temperature range of 25 - 60 °C, mix vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, silica, oil and emulsifier uniformly to form an oil phase. Take a part of deionized water, add a thickening agent, dissolve and swell it fully to form an aqueous phase. Mix the remaining deionized water and a preservative uniformly and add them to the aqueous phase. Within the temperature range of 25 - 60 °C, slowly add the aqueous phase into the oil phase, stir and homogenize for 5 - 15 minutes; continue to stir, slowly cool down to room temperature to form a milky cream, and store it sealed in the dark.

[0069] II. Dosage Form B

[0070] Dosage form B in the set for removing wrinkles and / or enhancing skin elasticity that takes effect in a short time described in this application is a product applied in the second step, and it contains a colloidal platinum composition and light-scattering particles.

[0071] Colloidal Platinum Composition

[0072] It is first discovered in this application that the selection of solvents and additives in the preparation process of the colloidal platinum composition is crucial. It is innovatively discovered in the present invention that by using specific solvents (for example, propylene glycol) and additives (for example, fatty acids and organosilanes), the particle size of the obtained colloidal platinum composition is within the range of 0.5 - 5 nm, and the composition can maintain long-term stability.

[0073] In some embodiments of the present invention, the content of the colloidal platinum composition in dosage form B of the set described in this application is 0.01 - 10% by weight. In some embodiments of the present invention, dosage form B of the set contains 0.01 - 5% by weight of the colloidal platinum composition. In some embodiments of the present invention, dosage form B of the set contains 1 - 5% by weight of the colloidal platinum composition.

[0074] Metal Platinum Salt of Colloidal Platinum Composition

[0075] The present invention provides a colloidal platinum composition, which contains colloidal platinum, a raw material dedicated to top cosmetics, as an active ingredient.

[0076] In an embodiment of the present invention, the metal platinum salt is selected from: chloroplatinic acid (cas: 16941-12-1, chemical formula: H2PtCl6·6H2O), potassium hexachloroplatinate (cas: 16921-30-5, chemical formula: K2PtCl6), sodium hexachloroplatinate (cas: 19583-77-8, chemical formula: Na2PtCl6·6H2O), platinum acetylacetonate (cas: 15170-57-7, chemical formula: C 10 H 14 O4Pt), or a combination thereof. In a preferred embodiment, the metal platinum salt is chloroplatinic acid.

[0077] In some embodiments of the present invention, the content of the metal platinum salt in the colloidal platinum composition described in the present application is 0.1-10% by weight. In some embodiments of the present invention, the colloidal platinum composition contains 0.1-8% by weight of the metal platinum salt. In some embodiments of the present invention, the composition contains 0.1-5% by weight of the metal platinum salt. In some embodiments of the present invention, the composition contains 0.1-4% by weight of the metal platinum salt.

[0078] Solvent of Colloidal Platinum Composition

[0079] Colloidal platinum is a liquid in which negatively charged platinum nanoparticles are suspended. The solvent used to prepare the colloidal platinum composition is usually ethylene glycol. For example, the use of ethylene glycol was reported in the literature (Nano Today, 2009, 4, 143-164). However, ethylene glycol has certain toxicity and can damage internal organs such as the kidneys, liver, stomach, and intestines of the human body. At the same time, ethylene glycol is a restricted-use organic solvent included in Appendix 2 of the second volume of the Chinese Pharmacopoeia 2010 edition.

[0080] Propylene glycol, whose INCI name is PROPYLENE GLYCOL. The present application unexpectedly found that using propylene glycol as the solvent for preparing the colloidal platinum composition can not only retain the advantages of propylene glycol such as non-toxicity, non-corrosion, degradability, and better safety, but also maintain the stability of the prepared colloidal platinum composition. Therefore, the present application first discovered that propylene glycol is the best solvent for preparing the colloidal platinum composition.

[0081] In some embodiments of the present invention, the amount of the solvent in the colloidal platinum composition described in the present application is equal to or greater than 50% by weight. In some embodiments of the present invention, the colloidal platinum composition contains 40-95% by weight of the solvent. In some embodiments of the present invention, the composition contains 50-90% by weight of the solvent. In some embodiments of the present invention, the composition contains 60-90% by weight of the solvent. In some embodiments of the present invention, the composition contains 70-90% by weight of the solvent.

[0082] Additive of Colloidal Platinum Composition

[0083] The present invention unexpectedly discovers that fatty acids and organosilanes play a crucial role in the preparation of colloidal platinum compositions.

[0084] The addition of fatty acids plays a crucial role in controlling the particle size in colloidal platinum.

[0085] Fatty acids are a class of compounds composed of carbon, hydrogen, and oxygen, and are the main components of neutral fats, phospholipids, and glycolipids. Fatty acid metabolism: Fatty acids can be further classified according to the length of the carbon chain as follows: short-chain fatty acids, with less than 6 carbon atoms on the carbon chain, also known as volatile fatty acids; medium-chain fatty acids, referring to fatty acids with 6 - 12 carbon atoms on the carbon chain, mainly composed of caprylic acid (C8) and capric acid (C10); long-chain fatty acids, with more than 12 carbon atoms on the carbon chain. In a preferred embodiment of the present invention, the additive used is medium-chain or long-chain fatty acids. In a preferred embodiment, fatty acids with 8 - 30 carbon atoms are used. In a more preferred embodiment, fatty acids with 10 - 26 carbon atoms are used. In a more preferred embodiment, fatty acids with 12 - 22 carbon atoms are used. In a specific embodiment, fatty acids with 12, 14, 16, 18, 20, 22 carbon atoms are used.

[0086] Fatty acids can be classified into 3 categories according to the saturation and unsaturation of the carbon-hydrogen chain, namely: saturated fatty acids, without unsaturated bonds on the carbon-hydrogen; monounsaturated fatty acids, with one unsaturated bond on the carbon-hydrogen chain; polyunsaturated fatty acids, with two or more unsaturated bonds on the carbon-hydrogen chain. Saturated, monounsaturated, or polyunsaturated fatty acids can be used in the colloidal platinum compositions of the present invention.

[0087] In a preferred embodiment, the fatty acid is selected from one of palmitic acid, oleic acid, stearic acid, lauric acid, behenic acid or a combination thereof. In the most preferred embodiment, the fatty acid is oleic acid.

[0088] In some embodiments of the present invention, the dosage of fatty acids in the colloidal platinum compositions described in the present application is 1 - 20% by weight. In some embodiments of the present invention, the colloidal platinum composition contains 1 - 15% by weight of fatty acids. In some embodiments of the present invention, the composition contains 2 - 15% by weight of fatty acids. In some embodiments of the present invention, the composition contains 3 - 10% by weight of fatty acids. In some embodiments of the present invention, the composition contains 5 - 10% by weight of fatty acids.

[0089] The addition of organosilanes helps to maintain the long-term stability of the activity of colloidal platinum.

[0090] In some embodiments of the present invention, an organosilane having 10 to 60 carbon atoms is used. In a preferred embodiment, an organosilane having 10 to 30 carbon atoms is used. In a more preferred embodiment, an organosilane having 10 to 26 carbon atoms is used. In a more preferred embodiment, an organosilane having 10 to 20 carbon atoms is used. In a specific embodiment, an organosilane having 11, 14, 17, or 20 carbon atoms is used.

[0091] In a preferred embodiment, the organosilane is selected from one of trimethoxyoctylsilane, triethoxyoctylsilane, or a combination thereof. In a more preferred embodiment, the organosilane is trimethoxyoctylsilane.

[0092] In some embodiments of the present invention, the amount of the organosilane in the colloidal platinum composition described in this application is 0.01 to 5% by weight. In some embodiments of the present invention, the colloidal platinum composition contains 0.01 to 1% by weight of the organosilane. In some embodiments of the present invention, the colloidal platinum composition contains 0.1 to 2% by weight of the organosilane. In some embodiments of the present invention, the composition contains 0.1 to 1% by weight of the organosilane. In some embodiments of the present invention, the composition contains 0.1 to 0.5% by weight of the organosilane.

[0093] Other Ingredients in Colloidal Platinum Composition

[0094] The colloidal platinum composition of the present invention may further contain other components.

[0095] For example, in one embodiment of the present invention, the composition further contains polyvinylpyrrolidone. Polyvinylpyrrolidone is abbreviated as PVP and is a non-ionic polymer compound. PVP is divided into four grades according to its average molecular weight, and is conventionally represented by the K value. Different K values represent the corresponding average molecular weight ranges of PVP. The K value is actually a characteristic value related to the relative viscosity of the PVP aqueous solution, and viscosity is a physical quantity related to the molecular weight of the polymer, so the average molecular weight of PVP can be characterized by the K value. Generally, the larger the K value, the greater its viscosity and the stronger its adhesiveness.

[0096] In a specific embodiment, the K value of the polyvinylpyrrolidone contained in the composition is required to be within the range of 28 to 34.

[0097] In some embodiments of the present invention, the amount of polyvinylpyrrolidone in the colloidal platinum composition described in this application is 1-30% by weight. In some embodiments of the present invention, the colloidal platinum composition contains 2-30% by weight of polyvinylpyrrolidone. In some embodiments of the present invention, the composition contains 2-20% by weight of polyvinylpyrrolidone. In some embodiments of the present invention, the composition contains 2-15% by weight of polyvinylpyrrolidone. In some embodiments of the present invention, the composition contains 1-10% by weight of polyvinylpyrrolidone.

[0098] Preparation Method of Colloidal Platinum Composition

[0099] The present invention also provides a method for preparing the above-mentioned colloidal platinum composition.

[0100] The colloidal platinum composition of the present invention can be prepared from raw materials in the following weight percentages: metal platinum salt 0.1%-4%, polyvinylpyrrolidone 2%-30%, propylene glycol 60%-90%, fatty acid 5%-15%, organosilane 0.01%-1%.

[0101] Specifically, the method for preparing the colloidal platinum composition of the present invention includes the following steps:

[0102] (a) Mix the metal platinum salt, polyvinylpyrrolidone, and propylene glycol to obtain a first mixture;

[0103] (b) Add the fatty acid to the first mixture to obtain a second mixture;

[0104] (c) Add the organosilane to the second mixture to finally obtain the colloidal platinum composition of the present invention.

[0105] In a specific embodiment, the method for preparing the colloidal platinum composition of the present invention includes the following steps: Under room temperature conditions, mix the metal platinum salt, polyvinylpyrrolidone, and propylene glycol evenly according to the above dosages. Stir rapidly and heat to 110-200 °C, and keep warm for 2-8 hours. Add the fatty acid, raise the temperature to 120-250 °C, and continue stirring for 30-90 minutes. Subsequently, cool down to 60-80 °C, add the organosilane, and keep stirring at this temperature for 30-90 minutes. Finally, cool down to room temperature. Discharge the material, and the preparation of the colloidal platinum is completed. Place it in a cool place and store it away from light.

[0106] The average particle size of the colloidal platinum composition prepared by the present invention is 0.5-5 nm. In a preferred embodiment, the average particle size of the colloidal platinum composition of the present invention is 1-5 nm. In a preferred embodiment, the average particle size of the colloidal platinum composition of the present invention is 1-3 nm.

[0107] More than 75% of the particles in the colloidal platinum composition prepared by the present invention have a particle size within the range of 1.75 ± 0.5 nm. In a preferred embodiment, more than 80% of the particles in the composition have a particle size within the range of 1.75 ± 0.5 nm. In a more preferred embodiment, more than 90% of the particles in the composition have a particle size within the range of 1.75 ± 0.5 nm.

[0108] Light Scattering Particles

[0109] Dosage form B in the set for wrinkle removal and / or skin elasticity enhancement that takes effect in a short time described in this application contains light-scattering particles. In some embodiments of the present invention, the light-scattering particles include: nylon-12 and isopropyl titanium triisostearate, silicone resin, or a combination of them.

[0110] In some embodiments of the present invention, the content of the light-scattering particles in dosage form B of the set described in this application is 1-10% by weight. In some embodiments of the present invention, dosage form A of the set contains 2-8% by weight of the light-scattering particles. In some embodiments of the present invention, dosage form A of the set contains 2-5% by weight of the light-scattering particles.

[0111] Other Ingredients in Dosage Form B

[0112] Dosage form B of the set of the present invention may also contain other components. For example, dosage form A of the set of this application may contain silicone oil, silicone elastomer, emulsifier, polyol, preservative, etc.

[0113] In some embodiments of the present invention, dosage form B of the set contains cyclopentasiloxane. In some specific embodiments, dosage form B contains 10-20% by weight of cyclopentasiloxane.

[0114] In some embodiments of the present invention, dosage form B of the set contains polydimethylsiloxane cross-linked polymer. In some specific embodiments, dosage form B contains 1-15% by weight of polydimethylsiloxane cross-linked polymer.

[0115] In some embodiments of the present invention, the polyol contained in dosage form B of the set is selected from: glycerol, butanediol, hexanediol, or a combination of them. In some specific embodiments, dosage form B contains 20-40% by weight of the polyol.

[0116] In some embodiments of the present invention, the emulsifier contained in dosage form B of the set is selected from: cetyl PEG / PPG-10 / 1 polydimethylsiloxane, polydimethylsiloxane PEG-10 / 15 cross-linked polymer, or a combination of them. In some specific embodiments, dosage form B contains 2-5% by weight of the emulsifier.

[0117] Preparation Method of Dosage Form B

[0118] The present invention also provides a method for preparing Formulation B.

[0119] Formulation B of the present invention can be prepared from the following raw materials in weight percentages: silicone oil 10 - 20%, silicone elastomer 1 - 15%, emulsifier 2 - 5%, light-scattering particles 2 - 8%, colloidal platinum composition 0.01 - 2%, polyol 20 - 40%, preservative 0.1 - 1%, deionized water 25 - 45%.

[0120] Specifically, the method for preparing Formulation B of the present invention includes the following steps:

[0121] (a) Mix silicone oil, silicone elastomer, emulsifier, and light-scattering particles evenly to obtain an oil phase;

[0122] (b) Take a portion of deionized water, add polyol and preservative, and dissolve them thoroughly to obtain a water phase;

[0123] (c) Prepare a colloidal platinum composition as an additive phase;

[0124] (d) Slowly add the water phase into the oil phase, and then add the additive phase to obtain Formulation B.

[0125] In a specific embodiment, the preparation process of Formulation B includes the following steps: within the temperature range of 25 - 60°C, mix silicone oil, silicone elastomer, emulsifier, and light-scattering particles evenly to obtain an oil phase. Take a portion of deionized water, add polyol and preservative, and dissolve them thoroughly to obtain a water phase. Add the colloidal platinum separately as an additive phase. Within the temperature range of 25 - 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 - 15 min; then add the additive phase, and continue to stir and homogenize for 5 - 15 min; form an opaque gel, and store it sealed away from light.

[0126] III. Application of the set

[0127] The present invention also relates to the application of the said set in the field of cosmetics. Specifically, the application method includes: first apply the product of Formulation A to the desired parts of the skin, and then apply the product of Formulation B to the desired areas.

[0128] In a specific embodiment, after the tester uses the set of the present invention (for example, after 15 minutes), both the skin roughness and the average depth value of skin wrinkles are significantly improved. Therefore, the product of the present invention has an immediate effect of helping to improve skin roughness and skin wrinkles. At the same time, the skin elasticity of the tester is also significantly improved, so the product of the present invention also has an immediate effect of enhancing skin elasticity.

[0129] In one embodiment, the application method of the anti-wrinkle and / or skin elasticity enhancing set of the present invention is as follows: First, apply the product of Formulation A to the skin around the eyes. After complete absorption, then apply the product of Formulation B to the desired area and wait for 3 - 10 minutes.

[0130] In addition, the anti-wrinkle and / or skin elasticity enhancing set of the present invention has achieved unexpected effects in the fields of removing crow's feet, enhancing the elasticity of the skin around the eyes, and improving eye bags.

[0131] Instantly remove wrinkles and achieve rejuvenation. Quickly eliminate eye bags and crow's feet. Gentle and non-irritating to the skin. The products applying this technology can form a transparent invisible film on the skin surface, quickly fill wrinkles, and lift and tighten the loose skin. Before and after use, the testers can show a 5 - 15-year age reduction in appearance. Enhance the confidence of modern urban women and radiate charming luster.

[0132] The following will further elaborate on the present invention in combination with specific embodiments. It is necessary to point out here that the embodiments are only used to further illustrate the present invention and should not be construed as limiting the protection scope of the present invention. Skilled technicians in this field can make some non-essential improvements and adjustments based on the content of the present invention above. The test methods without specific conditions noted in the following embodiments are usually carried out under conventional conditions or according to the conditions recommended by the manufacturers. Unless otherwise specified, all percentages and parts are by weight.

[0133] Example 1: Preparation of Colloidal Platinum Composition

[0134] Under room temperature conditions, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 85.5% propylene glycol evenly. Stir rapidly, heat to 110 °C, and keep warm for 2 hours. Add 8% oleic acid, raise the temperature to 120 °C, and continue stirring for 30 minutes. Subsequently, cool down to 60 °C, add 0.5% trimethoxyoctylsilane, and keep stirring at this temperature for 30 minutes. Finally, cool down to room temperature. Discharge the material, and the preparation of colloidal platinum is completed. Store it in a cool place away from light.

[0135] Comparative Example 1: Preparation of Colloidal Platinum Composition

[0136] Under room temperature conditions, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 86% propylene glycol evenly. Stir rapidly, heat to 110 °C, and keep warm for 2 hours. Add 8% oleic acid, raise the temperature to 120 °C, and continue stirring for 30 minutes. Finally, cool down to room temperature. Discharge the material, and the preparation of colloidal platinum is completed. Store it in a cool place away from light.

[0137] Comparative Example 2: Preparation of Colloidal Platinum Composition

[0138] At room temperature, 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 93.5% propylene glycol were mixed evenly. Stir quickly, heat to 110 °C, and keep warm for 2 hours. Subsequently, cool down to 60 °C, add 0.5% trimethoxyoctylsilane, and stir at this temperature for 30 minutes. Finally, cool down to room temperature. Discharge the material, and the preparation of colloidal platinum is completed. Place it in a cool place and store it away from light.

[0139] Comparative Example 3: Preparation of Colloidal Platinum Composition

[0140] At room temperature, 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 94% propylene glycol were mixed evenly. Stir quickly, heat to 110 °C, and keep warm for 2 hours. Finally, cool down to room temperature. Discharge the material, and the preparation of colloidal platinum is completed. Place it in a cool place and store it away from light.

[0141] Test Example 1: Investigation on the Stability of Colloidal Platinum Composition

[0142] The stability evaluation method is as follows: Place the colloidal platinum compositions prepared in Example 1 and Comparative Examples 1 - 3 in a constant temperature incubator stable at high temperature (40 °C) and observe for 30 days. Observe whether there is precipitation of particulate solids, blackening on the surface, stratification, etc. in the samples. If the sample shows no change normally before and after a certain time within 30 days, it is indicated as "ok", the appearance of particulate phenomenon is indicated as "precipitation", the appearance of local blackening in color is indicated as "blackening", and the appearance of two layers of liquid up and down is indicated as "stratification". The results are shown in the following table.

[0143] Table 1: Investigation on the Stability of Different Additives

[0144]

[0145] As shown in Table 1, by comparing the results of Example 1 and Comparative Example 1, it was found that if no organosilane was added as a stabilizer in the colloidal platinum composition, the colloidal platinum composition would show blackening after 30 days; by comparing the results of Example 1 and Comparative Example 2, it was found that if no fatty acid was added during the preparation of the colloidal platinum composition, solid precipitation and caking would occur after 7 days; by comparing the results of Example 1 and Comparative Example 3, it was shown that the addition of fatty acid and organosilane plays an important role in the stability of the colloidal platinum composition during the preparation process.

[0146] Example 2: Preparation of Colloidal Platinum Composition

[0147] At room temperature, 0.5% of potassium hexachloroplatinate, 3% of polyvinylpyrrolidone, and 90.2% of propylene glycol were mixed evenly. Stir rapidly, heat to 110 °C, and keep warm for 2 hours. Add 6% of stearic acid, raise the temperature to 120 °C, and continue stirring for 30 minutes. Subsequently, cool down to 60 °C, add 0.3% of triethoxysilane, and keep stirring at this temperature for 30 minutes. Finally, cool down to room temperature. Discharge the material, and the colloidal platinum is prepared. Place it in a cool place and store it away from light.

[0148] Example 3: Preparation of Colloidal Platinum Composition

[0149] At room temperature, 2.5% of sodium chloroplatinate, 15% of polyvinylpyrrolidone, and 67.5% of propylene glycol were mixed evenly. Stir rapidly, heat to 110 °C, and keep warm for 2 hours. Add 14% of lauric acid, raise the temperature to 120 °C, and continue stirring for 30 minutes. Subsequently, cool down to 60 °C, add 1% of trimethoxysilane, and keep stirring at this temperature for 30 minutes. Finally, cool down to room temperature. Discharge the material, and the colloidal platinum is prepared. Place it in a cool place and store it away from light.

[0150] Example 4: Preparation of Colloidal Platinum Composition

[0151] At room temperature, 3% of platinum acetylacetonate, 20% of polyvinylpyrrolidone, and 66.1% of propylene glycol were mixed evenly. Stir rapidly, heat to 110 °C, and keep warm for 2 hours. Add 10% of behenic acid, raise the temperature to 120 °C, and continue stirring for 30 minutes. Subsequently, cool down to 60 °C, add 0.9% of triethoxysilane, and keep stirring at this temperature for 30 minutes. Finally, cool down to room temperature. Discharge the material, and the colloidal platinum is prepared. Place it in a cool place and store it away from light.

[0152] Example 5: Preparation of Colloidal Platinum Composition

[0153] At room temperature, 0.5% of chloroplatinic acid, 0.2% of platinum acetylacetonate, 10% of polyvinylpyrrolidone, and 76.5% of propylene glycol were mixed evenly. Stir rapidly, heat to 110 °C, and keep warm for 2 hours. Add 2% of palmitic acid and 10% of oleic acid, raise the temperature to 120 °C, and continue stirring for 30 minutes. Subsequently, cool down to 60 °C, add 0.8% of trimethoxysilane, and keep stirring at this temperature for 30 minutes. Finally, cool down to room temperature. Discharge the material, and the colloidal platinum is prepared. Place it in a cool place and store it away from light.

[0154] Example 6: Preparation of Colloidal Platinum Composition

[0155] At room temperature, 0.1% sodium chloroplatinate, 0.1% platinum acetylacetonate, 3% polyvinylpyrrolidone, and 92.7% propylene glycol were mixed evenly. Stir quickly, heat to 110 °C, and keep warm for 2 hours. Add 1% stearic acid and 3% oleic acid, raise the temperature to 120 °C, and continue stirring for 30 minutes. Subsequently, cool down to 60 °C, add 0.1% trimethoxyoctylsilane, and keep stirring at this temperature for 30 minutes. Finally, cool down to room temperature. Discharge the material, and the preparation of colloidal platinum is completed. Place it in a cool place and store it away from light.

[0156] Example 7: Preparation of Colloidal Platinum Composition

[0157] At room temperature, 2% chloroplatinic acid, 2% sodium chloroplatinate, 30% polyvinylpyrrolidone, and 50% propylene glycol were mixed evenly. Stir quickly, heat to 110 °C, and keep warm for 2 hours. Add 15% oleic acid, raise the temperature to 120 °C, and continue stirring for 30 minutes. Subsequently, cool down to 60 °C, add 1% trimethoxyoctylsilane, and keep stirring at this temperature for 30 minutes. Finally, cool down to room temperature. Discharge the material, and the preparation of colloidal platinum is completed. Place it in a cool place and store it away from light.

[0158] Test Example 2: Investigation on the Stability of Colloidal Platinum Composition

[0159] The stability evaluation method is as follows: Place the colloidal platinum compositions prepared in Examples 2 - 7 in a constant temperature oven stable at high temperature (40 °C) and observe for 30 days. Observe whether there is precipitation of particulate solids, blackening on the surface, stratification, etc. in the samples. If the sample remains normal without change around a certain time within 30 days, it is indicated as "ok", the appearance of particulate phenomenon is indicated as "precipitation", the appearance of local blackening in color is indicated as "blackening", and the appearance of two layers of liquid up and down is indicated as "stratification". The results are shown in Table 2 below.

[0160] Table 2: Investigation on the Stability of Different Preparation Raw Materials

[0161]

[0162]

[0163] As shown in Table 2, from the results of Examples 2 to 5, it is found that the metal platinum salt selected in the colloidal platinum can be one of chloroplatinic acid, potassium hexachloroplatinate, sodium chloroplatinate, and platinum acetylacetonate, and all can achieve good results; from the results of Examples 4, Example 6, and Example 7, it is found that by selecting trimethoxyoctylsilane and triethoxyoctylsilane, colloidal platinum compositions with good stability can be obtained; by comparing all the above results, it shows that in the process of preparing colloidal platinum, the fatty acid can be selected from palmitic acid, oleic acid, stearic acid, lauric acid, and behenic acid, and all can achieve satisfactory results.

[0164] The colloidal platinum composition obtained from the above experiments not only has good stability, but its activity can still maintain a relatively high level. Since colloidal platinum can promote the crosslinking reaction of siloxane, a cosmetic containing siloxane is used as the first dosage form (dosage form A), and then a cosmetic containing the colloidal platinum composition is used as the second dosage form (dosage form B).

[0165] In this study, a dual-dosage form product was designed, namely dosage form A containing siloxane and dosage form B containing the colloidal platinum composition. Apply the dosage form A product to the designated skin area in advance, and then apply the dosage form B product to the same area. The colloidal platinum composition can promote the crosslinking of siloxane on the skin surface, and can achieve the cosmetic effects of instant firming, lifting and wrinkle removal.

[0166] The following are the specific application examples of the colloidal platinum composition in skin topical agents in this invention, as well as the formulations and preparation methods of these dosage forms. In the following tables, "-" means no addition.

[0167] Table 3: Formulation table of dosage form A (Product Examples 4 / 5 / 6 / 7, Application Example 1)

[0168]

[0169]

[0170] Table 4: Formulation tables of dosage form B of Product Examples 4-7 and dosage form B of Application Example 1

[0171]

[0172]

[0173] Product Example 4:

[0174] Preparation of dosage form A

[0175] According to the above formula dosages, within the temperature range of 25°C to 60°C, 20% vinyl polydimethylsiloxane (viscosity: 10000 cSt), 10% hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 10% polydimethylsiloxane, and 4% polydimethylsiloxane PEG-10 / 15 crosslinked polymer were fully mixed evenly as the oil phase. Take 30% deionized water, add acrylate / C10-30 alkanol acrylate crosslinked polymer, and dissolve and swell fully as the water phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol evenly, and continue to add the water phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 min; continue to stir, and slowly cool down to room temperature to form a milky cream, and store it sealed and away from light.

[0176] Preparation of Dosage Form B

[0177] In the temperature range of 45°C to 60°C, mix 15% of cyclopentasiloxane, 1% of polydimethylsiloxane cross-linked polymer, 4% of cetyl PEG / PPG-10 / 1 dimethicone, and 1% of polydimethylsiloxane PEG-10 / 15 cross-linked polymer evenly to form the oil phase. Dissolve 57.4% of deionized water, 5% of glycerol, 15% of butanediol, 0.3% of phenoxyethanol, and 0.3% of ethylene glycol fully to form the water phase. Add 1% of the colloidal platinum composition of Example 1 separately as the additive phase. In the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 minutes; then add the additive phase and continue to stir and homogenize for 5 to 15 minutes; form an opaque gel and store it sealed in the dark.

[0178] Product Example 5:

[0179] Preparation of Dosage Form A

[0180] According to the above formula dosage, in the temperature range of 25°C to 60°C, mix 20% of vinyl polydimethylsiloxane (viscosity: 180000 cSt), 10% of hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 10% of polydimethylsiloxane, and 4% of polydimethylsiloxane PEG-10 / 15 cross-linked polymer evenly to form the oil phase. Take 30% of deionized water, add acrylic (ester) / C10-30 alkyl acrylate cross-linked polymer, and dissolve and swell it fully to form the water phase. Mix the remaining deionized water, 0.25% of tromethamine, 0.4% of phenoxyethanol, and 0.5% of hexylene glycol evenly, and then continue to add the water phase. In the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue to stir and slowly cool down to room temperature to form a milky cream, and store it sealed in the dark.

[0181] Preparation of Dosage Form B

[0182] In the temperature range of 45°C to 60°C, mix 15% of cyclopentasiloxane, 1% of polydimethylsiloxane cross-linked polymer, 4% of cetyl PEG / PPG-10 / 1 dimethicone, and 1% of polydimethylsiloxane PEG-10 / 15 cross-linked polymer evenly to form the oil phase. Dissolve 57.4% of deionized water, 5% of glycerol, 15% of butanediol, 0.3% of phenoxyethanol, and 0.3% of ethylene glycol fully to form the water phase. Add 1% of the colloidal platinum composition of Example 1 separately as the additive phase. In the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 minutes; then add the additive phase and continue to stir and homogenize for 5 to 15 minutes; form an opaque gel and store it sealed in the dark.

[0183] Product Example 6:

[0184] Preparation of Dosage Form A

[0185] According to the above formula dosages, within the temperature range of 25°C to 60°C, 20% vinyl polydimethylsiloxane (viscosity: 60000 cSt), 10% hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 10% polydimethylsiloxane, and 4% polydimethylsiloxane PEG-10 / 15 cross-linked polymer were fully mixed evenly to serve as the oil phase. Take 30% deionized water, add acrylate / C10-30 alkyl acrylate cross-linked polymer, and dissolve and swell it fully to serve as the water phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol evenly, and then continue to add the water phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 min; continue to stir, slowly cool down to room temperature, form a milky cream, and store it sealed and away from light.

[0186] Preparation of Dosage Form B

[0187] Within the temperature range of 45°C to 60°C, 15% cyclopentasiloxane, 1% polydimethylsiloxane cross-linked polymer, 4% cetyl PEG / PPG-10 / 1 polydimethylsiloxane, and 1% polydimethylsiloxane PEG-10 / 15 cross-linked polymer were mixed evenly to serve as the oil phase. Mix 57.4% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol until fully dissolved to serve as the water phase. Add 1% of the colloidal platinum composition of Example 1 separately to serve as the additive phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 min; then add the additive phase, continue to stir and homogenize for 5 to 15 min; form an opaque gel, and store it sealed and away from light.

[0188] Product Example 7:

[0189] Preparation of Dosage Form A

[0190] According to the above formula dosage, within the temperature range of 25°C to 60°C, 20% of vinyl polydimethylsiloxane (viscosity: 60000 cSt), 10% of hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 10% of polydimethylsiloxane, 4% of polydimethylsiloxane PEG-10 / 15 crosslinked polymer, and 8% of silica are fully mixed evenly to form the oil phase. Take 25% of deionized water, add 0.5% of acrylate / C10-30 alkyl acrylate crosslinked polymer, and dissolve and swell it fully to form the water phase. Mix the remaining deionized water, 0.25% of tromethamine, 0.4% of phenoxyethanol, and 0.5% of hexylene glycol evenly, and then continue to add the water phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue to stir, and slowly cool down to room temperature to form a milky cream, which is stored sealed and away from light.

[0191] Preparation of Dosage Form B

[0192] Within the temperature range of 45°C to 60°C, 15% of cyclopentasiloxane, 1% of polydimethylsiloxane crosslinked polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, and 1% of polydimethylsiloxane PEG-10 / 15 crosslinked polymer are mixed evenly to form the oil phase. Mix 57.4% of deionized water, 5% of glycerol, 15% of butanediol, 0.3% of phenoxyethanol, and 0.3% of ethylene glycol until fully dissolved to form the water phase. Add 1% of the colloidal platinum composition of Example 1 separately as the additive phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 minutes; then add the additive phase, and continue to stir and homogenize for 5 to 15 minutes; form an opaque gel, which is stored sealed and away from light.

[0193] Application Example 1:

[0194] Preparation of Dosage Form A

[0195] According to the above formula dosage, within the temperature range of 25°C to 60°C, 20% vinyl polydimethylsiloxane (viscosity: 60000 cSt), 10% hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 10% polydimethylsiloxane, 4% polydimethylsiloxane PEG-10 / 15 crosslinked polymer, and 8% silica are fully mixed evenly to form the oil phase. Take 25% deionized water, add 0.5% acrylate / C10-30 alkyl acrylate crosslinked polymer, and dissolve and swell it fully to form the water phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol evenly, and then continue to add the water phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 min; continue stirring, and slowly cool down to room temperature to form a milky white cream, and store it sealed and away from light.

[0196] Preparation of Dosage Form B

[0197] Within the temperature range of 45°C to 60°C, 15% cyclopentasiloxane, 1% polydimethylsiloxane crosslinked polymer, 4% cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% polydimethylsiloxane PEG-10 / 15 crosslinked polymer, 4.5% nylon-12, and isopropyl triisostearoyl titanate are mixed evenly to form the oil phase. Mix 52.9% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol until fully dissolved to form the water phase. Add 1% of the colloidal platinum composition of Example 1 separately as the additive phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 min; then add the additive phase, and continue stirring and homogenizing for 5 to 15 min; form an opaque gel, and store it sealed and away from light.

[0198] Test Example 3: Improvement Rates of Skin Elasticity and Average Wrinkle Depth

[0199] The efficacy evaluation of the product is compared by the improvement effects on eye wrinkles and skin elasticity. The wrinkles are measured using a Primos Pico instrument, and the skin elasticity is tested using a Cutometer instrument. Among them, the introduction of the Primos Pico for skin wrinkles is as follows: The skin rapid three-dimensional imaging system Primos is a digital optical three-dimensional image analysis instrument developed based on a digital microscopic fringe projector. The testing principle of the Cutometer instrument for skin elasticity is based on the suction and stretching principle. A negative pressure is generated on the surface of the tested skin to suck the skin into a specific test probe. The depth at which the skin is sucked into the test probe is measured by a non-contact optical testing system. The measurement indicators and meanings of the Primos Pico for skin wrinkles and the Cutometer for skin elasticity are summarized in the following table:

[0200] Table 5: Measurement indicators and meanings of the Primos Pico for skin wrinkles and the Cutometer for skin elasticity

[0201]

[0202] The evaluation method for the skin elasticity improvement rate is as follows: Product Examples 4 - 7 (Dosage Forms A and B) and Application Example 1 (Dosage Forms A and B) are used in combination, with a total of 5 groups of experiments. The testing method for human efficacy is as follows:

[0203] 1. Skin test volunteers first clean their faces with a facial cleanser and then adapt for 15 minutes in an environment with constant temperature and humidity.

[0204] 2. Use the Cutometer instrument to record the first test of the eye skin elasticity as the initial value. Use the Primos Pico instrument to record the average wrinkle depth value around the eye skin as the initial value.

[0205] 3. Apply the product around the eye area. First, apply 70 μL of Dosage Form A to the area of the crow's feet at the corners of the eyes and wait for 3 - 5 minutes until it is completely absorbed. Then, apply 100 μL of Dosage Form B, covering the skin area containing Dosage Form A, and wait for about 3 - 10 minutes.

[0206] 4. After all the samples are applied, rest for 15 minutes in an environment with constant temperature and humidity, and then conduct the second test to record the elasticity value and the average wrinkle depth.

[0207] 5. The test is completed.

[0208] The calibration improvement rate is used to reflect the percentage of skin changes. The larger the value, the more significant the improvement.

[0209]

[0210] Table 6

[0211] Number Test Sample R2 R7 Average Wrinkle Depth Improvement Rate 1 Product Example 4 10.61％ 8.81％ 6.52％ 2 Product Example 5 13.05％ 10.85％ 7.62％ 3 Product Example 6 18.88％ 16.17％ 10.34％ 4 Product Example 7 23.51％ 21.15％ 10.51％ 5 Application Example 1 23.68％ 21.88％ 12.82％

[0212] As shown in the above table, after the products of dosage form A and dosage form B are used in combination, 15 minutes later, both the skin elasticity and the average wrinkle depth are significantly improved.

[0213] Through three groups of experiments numbered 1 / 2 / 3, it was found that the use of vinyl polydimethylsiloxane with different viscosities in dosage form A had a greater impact on the results; whether using vinyl polydimethylsiloxane with a relatively low viscosity (10,000 cSt) (Product Example 4, Dosage Form A, No. 1), or using vinyl polydimethylsiloxane with a relatively high viscosity (180,000 cSt) (Product Example 5 - Dosage Form A, No. 2), the results were not as good as those obtained with vinyl polydimethylsiloxane with a relatively medium viscosity (60,000 cSt) (Product Example 6, Dosage Form A, No. 3). Therefore, the viscosity requirement of the raw material vinyl polydimethylsiloxane in dosage form A is within a relatively medium viscosity range (the viscosity index requirement is a viscosity of 55,000 to 95,000 cSt at 25°C), which has the most obvious improvement effect on skin elasticity and average wrinkle depth.

[0214] Based on the experimental results of No. 3 and No. 4, two different dosage forms of A are used in combination with the same dosage form of B. Since the main difference between Product Example 6, Dosage Form A (No. 3) and Product Example 7, Dosage Form A (No. 4) is that Product Example 7, Dosage Form A additionally contains 8% silica, the combination of Group No. 4 (Product Example 7, Dosage Form A and Dosage Form B) can significantly be higher than the combination of Group No. 3 (Product Example 6 - Dosage Form A, Dosage Form B) in terms of skin elasticity indicators (R2 and R7). Therefore, the addition of silica in the formulated dosage form A has a significant promoting effect on the improvement of skin elasticity.

[0215] Based on the experimental results of two groups numbered 4 and 5, the same formulation of dosage form A is used, and two different products of dosage form B are used instead. The improvement effects of the two groups of experimental results on skin elasticity (R2 and R7) are relatively close, but there are certain differences in terms of the average wrinkle depth (improvement rate of Ave. Wrinkle. Depth). Compared with Dosage Form B in No. 4 (Product Example 7), Dosage Form B in No. 5 (Application Example 1) has an additional 4.5% addition of light-scattering particles (nylon-12 and isopropyl titanium triisostearate) in its formulation structure. Therefore, the addition of light-scattering particles in dosage form B is beneficial to the improvement of the average wrinkle depth. Combining Figure 1-2 with the results, the product of Application Example 1 has a significant improvement effect on both skin elasticity and average wrinkle depth.

[0216] Application Example 2:

[0217] Preparation of Dosage Form A

[0218] According to the above formula dosage, within the temperature range of 25°C to 60°C, 35% vinyl polydimethylsiloxane (viscosity: 65000 cSt), 25% hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 10% polydimethylsiloxane, 4% polydimethylsiloxane PEG-10 / 15 cross-linked polymer, and 10% silylated silica are fully mixed evenly to serve as the oil phase. Take 10% deionized water, add 0.2% acrylate / C10-30 alkanol acrylate cross-linked polymer, and dissolve and swell it fully to serve as the water phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol evenly, and then continue to add the water phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 min; continue stirring, and slowly cool down to room temperature to form a milky cream, and store it sealed and away from light.

[0219] Preparation of Dosage Form B

[0220] Within the temperature range of 45°C to 60°C, 15% cyclopentasiloxane, 1% polydimethylsiloxane cross-linked polymer, 4% cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% polydimethylsiloxane PEG-10 / 15 cross-linked polymer, 4.5% nylon-12, and isopropyl titanium triisostearate are mixed evenly to serve as the oil phase. Dissolve 48.9% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol fully to serve as the water phase. Add 5% of the colloidal platinum composition of Example 1 separately to serve as the additive phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 min; then add the additive phase, and continue to stir and homogenize for 5 to 15 min; form an opaque gel, and store it sealed and away from light.

[0221] Application Example 3:

[0222] Preparation of Dosage Form A

[0223] According to the above formula dosages, within the temperature range of 25°C to 60°C, 5% vinyl polydimethylsiloxane (viscosity: 80000 cSt), 3% hydrogenated polydimethylsiloxane (viscosity: 100 cSt), 10% polydimethylsiloxane, 2% polydimethylsiloxane PEG-10 / 15 cross-linked polymer, and 1% dimethylsilylated silica are fully mixed evenly to serve as the oil phase. Take 50% deionized water, add 0.5% acrylate / C10-30 alkanol acrylate cross-linked polymer, and dissolve and swell it fully to serve as the water phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol evenly, and then continue to add the water phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue stirring, and slowly cool down to room temperature to form a milky white cream, and store it sealed and away from light.

[0224] Preparation of Dosage Form B

[0225] Within the temperature range of 45°C to 60°C, 15% cyclopentasiloxane, 1% polydimethylsiloxane cross-linked polymer, 4% cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% polydimethylsiloxane PEG-10 / 15 cross-linked polymer, 4.5% nylon-12, and isopropyl titanium triisostearate are mixed evenly to serve as the oil phase. Mix 53.8% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol until fully dissolved to serve as the water phase. Add 0.1% of the colloidal platinum composition of Example 1 separately to serve as the additive phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 minutes; then add the additive phase, and continue stirring and homogenizing for 5 to 15 minutes; form an opaque gel, and store it sealed and away from light.

[0226] Application Example 4:

[0227] Preparation of Dosage Form A

[0228] According to the above formula dosages, within the temperature range of 25°C to 60°C, 20% of vinyl polydimethylsiloxane (viscosity: 80000 cSt), 10% of hydrogenated polydimethylsiloxane (viscosity: 15 cSt), 10% of polydimethylsiloxane, 4% of polydimethylsiloxane PEG-10 / 15 cross-linked polymer, and 5% of polydimethylsiloxane silylated silica are fully mixed evenly to serve as the oil phase. Take 30% of deionized water, add 0.5% of acrylate / C10-30 alkyl acrylate cross-linked polymer, and dissolve and swell it fully to serve as the water phase. Mix the remaining deionized water, 0.25% of tromethamine, 0.4% of phenoxyethanol, and 0.5% of hexylene glycol evenly, and then continue to add the water phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue to stir, and slowly cool down to room temperature to form a milky cream, and store it sealed and away from light.

[0229] Preparation of Dosage Form B

[0230] Within the temperature range of 45°C to 60°C, 15% of cyclopentasiloxane, 1% of polydimethylsiloxane cross-linked polymer, 4% of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% of polydimethylsiloxane PEG-10 / 15 cross-linked polymer, and 3% of silicone resin particles are fully mixed evenly to serve as the oil phase. Dissolve 53.4% of deionized water, 5% of glycerol, 15% of butanediol, 0.3% of phenoxyethanol, and 0.3% of ethylene glycol fully to serve as the water phase. Add 2% of the colloidal platinum composition of Example 1 separately to serve as the additive phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 minutes; then add the additive phase, and continue to stir and homogenize for 5 to 15 minutes; form an opaque gel, and store it sealed and away from light.

[0231] Application Example 5:

[0232] Preparation of Dosage Form A

[0233] According to the above formula dosage, within the temperature range of 25°C to 60°C, 12% vinyl polydimethylsiloxane (viscosity: 65000 cSt), 8% hydrogenated polydimethylsiloxane (viscosity: 45 cSt), 10% polydimethylsiloxane, 4% polydimethylsiloxane PEG-10 / 15 cross-linked polymer, and 5% polydimethylsiloxane silylated silica are fully mixed evenly to serve as the oil phase. Take 30% deionized water, add 0.5% acrylate / C10-30 alkanol acrylate cross-linked polymer, and dissolve and swell it fully to serve as the water phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol evenly, and then continue to add the water phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 minutes; continue to stir, and slowly cool down to room temperature to form a milky cream, which is stored sealed and away from light.

[0234] Preparation of Dosage Form B

[0235] Within the temperature range of 45°C to 60°C, 15% cyclopentasiloxane, 1% polydimethylsiloxane cross-linked polymer, 4% cetyl PEG / PPG-10 / 1 polydimethylsiloxane, 1% polydimethylsiloxane PEG-10 / 15 cross-linked polymer, 10% nylon-12, and isopropyl titanium triisostearate are mixed evenly to serve as the oil phase. Mix 47.4% deionized water, 5% glycerol, 15% butanediol, 0.3% phenoxyethanol, and 0.3% ethylene glycol and dissolve them fully to serve as the water phase. Add 1% of the colloidal platinum composition of Example 5 separately to serve as the additive phase. Within the temperature range of 25°C to 60°C, slowly add the water phase into the oil phase, stir and homogenize for 5 to 15 minutes; then add the additive phase, and continue to stir and homogenize for 5 to 15 minutes; form an opaque gel, which is stored sealed and away from light.

[0236] Test Example 4: Improvement Rates of Skin Elasticity and Average Wrinkle Depth

[0237] The efficacy evaluation of the product is compared through the improvement effects on canthus wrinkles and skin elasticity. The specific test method and usage are the same as described in Test Example 2. The results are shown in the following table:

[0238] Table 7

[0239]

[0240] From the test results of Nos. 1 to 4, it can be seen that the test samples of Application Examples 2 to 5 have obvious improvement effects on skin elasticity and average wrinkle depth.

Claims

1. A kit for removing wrinkles and / or improving skin elasticity, comprising: (i) Dosage Form A, comprising: 10-20% by weight of fat, 3-25% by weight of hydrogenated polydimethylsiloxane having a viscosity of 10 to 130 cSt at 25°C, 5-35% by weight of vinyl polydimethylsiloxane having a viscosity of 55,000 to 95,000 cSt at 25°C, 1-10% by weight of an emulsifier, 1-10% by weight of silica, and A cosmetically acceptable carrier; and (ii) Dosage Form B, comprising: 1-10% by weight of a colloidal platinum composition, 1-10% by weight of light scattering particles, A carrier acceptable in the cosmetic field; in, The colloidal platinum composition comprises: 0.1-10% by weight of a metal platinum salt or chloroplatinic acid, 1-20% by weight of fatty acids having 8-30 carbon atoms, 0.01-5% by weight of an organosilane having 10-60 carbon atoms, A solvent acceptable in the cosmetic field, said solvent being propylene glycol, Wherein, the metal platinum salt is selected from: potassium hexachloroplatinate, sodium chloroplatinate, platinum acetylacetonate or a combination thereof.

2. The set according to claim 1, wherein: The emulsifier in Formulation A is dimethicone PEG-10 / 15 crosspolymer.

3. The set according to claim 1, wherein: The silica in the dosage form A is selected from the group consisting of silica silylate, silica dimethyl silylate, silica polydimethylsiloxane silylate, hydrated silica or a combination thereof.

4. The set according to claim 1, wherein: The colloidal platinum composition in Formulation B further comprises polyvinyl pyrrolidone having a K value of 28-34.

5. The kit according to claim 1, wherein: The fatty acid in the colloidal platinum composition in the dosage form B is selected from palmitic acid, oleic acid, stearic acid, lauric acid, behenic acid or a combination thereof.

6. The kit according to claim 1, wherein: The organosilane in the colloidal platinum composition in the formulation B is selected from: trimethoxyoctylsilane, triethoxyoctylsilane or a combination thereof.

7. The set according to claim 1, wherein: The light scattering particles in the formulation B are nylon-12 and isopropyl titanium triisostearate.

8. The set according to claim 1, wherein: The formulation B further comprises the following ingredients: silicone oil, silicone elastomer, emulsifier, polyol or a combination thereof.

9. The set according to any one of claims 1 to 8, wherein the set is in a double-dose package or two independent packages.

Images